Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 8, 2008, Pages 1089-1095

  Du, Rong Hui ^a,b   Yi, Hong Wei ^a   Dai, De Zai ^b   Tang, Wei Hua ^a   Dai, Yin ^b  

^a NANJING UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BERBERINE; CATALASE; CPU 86017; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME; GLUTATHIONE PEROXIDASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; POTASSIUM CHANNEL HERG; PREPROENDOTHELIN 1; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; THYROXINE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; INFLAMMATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; ASPARTIC ENDOPEPTIDASES; BERBERINE; CARDIOMEGALY; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ETHER-A-GO-GO POTASSIUM CHANNELS; INFLAMMATION MEDIATORS; MALE; METALLOENDOPEPTIDASES; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; THYROXINE; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; VENTRICULAR FIBRILLATION;

EID: 47949124092     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.8.0015     Document Type: Article

References (39)

1. Anderson, R., Ramafi, G., Theron, A. J. (1996) Membrane stabilizing, anti-oxidative interactions of propranolol and dexpropranolol with neutrophils. Biochem. Pharmacol. 52: 341-349
2. Bar-Cohen, Y., Silka, M. J. (2006) Congenital long QT syndrome: diagnosis and management in pediatric patients. Curr. Treat. Options Cardiovasc. Med. 8: 387-395
3. Bird, I. M. (2005) Extraction of RNA from cells and tissue. Methods Mol. Med. 108: 139-148
4. Cerrone, M., Noujaim, S., Jalife, J. (2006) The short QT syndrome as a paradigm to understand the role of potassium channels in ventricular fibrillation. J. Intern. Med. 259: 24-38
5. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., Keating, M. T. (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80: 795-803
6. Dai, D. Z. (2006) CPU-86017: a novel Class III antiarrhythmic agent with multiple actions at ion channels. Cardiovasc. Drug. Rev. 24: 101-115
7. Dai, D. Z., Yu, F. (2005) Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias. Acta. Pharmacol. Sin. 26: 918-925
8. Dai, D. Z., Hu, H. J., Zhao, J., Hao, X. M., Yang, D. M., Zhou, P. A., Wu, C. H. (2004) Blockade of L-type calcium channel in myocardium and calcium-induced contractions of vascular smooth muscle by CPU 86017. Acta. Pharmacol. Sin. 25: 416-423
9. Du, R. H., Cibangu, D. C., Dai, D. Z., Lin, S., Guan, L. (2005) CPU-86017 improves the compromised blood-brain barrier permeability mediated by impaired endothelial NO system and oxidative stress caused by L-Thyroxin. Drug Dev. Res. 64: 145-156
10. Feng, Y., Tang, X. Y., Dai, D. Z., Dai, Y. (2007a) Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors. Acta Pharmacol. Sin. 28: 1746-1754
11. Feng, Y., Dai, D. Z., Na, T., Cui, B., Wang, T., Zhang, Y., Dai, Y. (2007b) Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy. Pharmacol. Rep. 59: 306-14
12. Gallagher, S.R. (2006) One-dimensional SDS gel electrophoresis of proteins. Curr. Protoc. Mol. Biol. 10: 10.2A
13. Gao, D. S., Fang, W. Y., Chiu-Man, C., Kirsh, J., Gross, G., Hamilton, R. M. (2007) QT hysteresis in long-QT syndrome children with exercise testing. Chin. Med. J. (Engl.) 120: 179-182
14. Geronikaki, A. A., Gavalas, A. M. (2006) Antioxidants and inflammatory disease: synthetic and natural antioxidants with anti-inflammatory activity. Comb. Chem. High Throughput Screen. 9: 425-442
15. Giustetto, C., Di Monte, F., Wolpert, C., Borggrefe, M., Schimpf, R., Sbragia, P., Leone, G., Maury, P., Anttonen, O., Haissaguerre, M., Gaita, F. (2006) Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur. Heart. J. 27: 2440-2447
16. Hao, J. M., Dai, D. Z., Yu, F. (2005) An exaggerated oxidative stress is induced in the myocardium by L-thyroxin and suppressed by CPU86017, a derivative of tetrahydroberberine. Adv. Pharmacy (Chinese) 29: 417-421
17. Hobbs, J. B., Peterson, D. R., Moss, A. J., McNitt, S., Zareba, W., Goldenberg, I., Qi, M., Robinson, J. L., Sauer, A. J., Ackerman, M. J., Benhorin, J., Kaufman, E. S., Locati, E. H., Napolitano, C., Priori, S. G., Towbin, J. A., Vincent, G. M., Zhang, L. (2006) Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 296: 1249-1254
18. Horkay, F., Gellér, L., Kiss, O., Szabó, T., Vagó H., Kékesi, V., Juhász-Nagy, A., Merkely, B. (2000) Bosentan the mixed endothelin-A- and -B-receptor antagonist suppresses intrapericardial endothelin-1-induced ventricular arrhythmias. J. Cardiovasc. Pharmacol. 36 (5 Suppl 1): S320-322
19. Hua, Z., Wang, X. L. (1994) Inhibitory effect of berberine on potassium channels in guinea pig ventricular myocytes (Chinese). Yao Xue Xue Bao 29: 576-580
20. Khan, R., Sheppard, R. (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-β1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 118: 10-24
21. Koo, S. H., Teo, W. S., Ching, C. K., Chan, S. H., Lee, E. J. (2007) Mutation screening in KCNQ1, HERG, KCNE1, KCNE2 and SCN5A genes in a long QT syndrome family. Ann. Acad. Med. Singapore 36: 394-398
22. Kuo, C. L., Chi, C. W., Liu, T. Y. (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 203: 127-137
23. Lehnart, S. E., Terrenoire, C., Reiken, S., Wehrens, X. H., Song, L. S., Tillman, E. J., Mancarella, S., Coromilas, J., Lederer, W. J., Kass, R. S., Marks, A. R. (2006) Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc. Natl Acad. Sci. USA 103: 7906-7910
24. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. (1951) Protein measurement with Folin phenol reagent. J. Biol. Chem. 193: 256-275
25. Mohácsi, A., Magyar, J., Tamás, B., Nánási, P. P. (2004) Effects of endothelins on cardiac and vascular cells: new therapeutic target for the future? Curr. Vasc. Pharmacol. 2: 53-63
26. Na, T., Dai, D. Z., Tang, X. Y., Dai, Y. (2007) Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU-86017. Naunyn Schmiedebergs Arch. Pharmacol. 375: 39-49
27. Oliveira, M., Antunes, E., da Silva, M. N. (1999) Prevention of sudden death in congenital long-QT syndrome. Rev. Port. Cardiol. 18: 627-633
28. Schwartz, P. J. (2005) The long QT syndrome: a clinical counterpart of hERG mutations. Novartis. Found. Symp. 266: 186-198
29. Taglialatela, M., Castaldo, P., Iossa, S., Pannaccione, A., Fresi, A., Ficker, E, Annunziato, L. (1997) Regulation of the human ether-a-go-go related gene (HERG) K1 channels by reactive oxygen species. Proc. Natl Acad. Sci. USA 94: 11698-11703
30. 1 channels as pharmacological targets - present and future implications. Biochem. Pharmacol. 55: 1741-1746
31. Tamargo, J., Caballero, R., Gomez, R., Valenzuela, C., Delpon, E. (2004) Pharmacology of cardiac potassium channels. Cardiovasc. Res. 62: 9-33
32. Wehrens, X. H. (2007) Leaky ryanodine receptors cause delayed afterdepolarizations and ventricular arrhythmias. Eur. Heart J. 8: 1054-1061
33. Witchel, H. J. (2007) The hERG potassium channel as a therapeutic target. Expert. Opin. Ther. Targets 11: 321-336
34. Wolbrette, D. L. (2004) Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death. Curr. Cardiol. Rep. 6: 379-384
35. Xia, H. J., Dai, D. Z., Dai, Y. (2006) Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in 1-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats. Life Sci. 2006; 79: 1812-1819
36. Xu, S. Z., Zhang Y., Ren J. Y., Zhou Z. N. (1997) Effects of berberine of L- and T-type calcium channels in guinea pig ventricular myocytes. Zhongguo Yao Li Xue Bao 18: 515-518
37. Yu, F., Dai, D. Z., An, L. F., Guo, X. F. (1997) Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats. Acta Pharmacol. Sin. 18: 71-74
38. Zhang, G. Q., Ma, Y. P., Hao, J. M., Zhou, P. A., Wu, C. H., Dai, D. Z. (2000) Rapidly activating delayed rectifier K+ current in cardiomyocytes from hypertrophied guinea pig hearts induced by thyroxin. J. China. Pharma. Univ. 31: 451-454
39. Zhang, T. T., Cui, B., Dai, D. Z., Tang, X. Y. (2005) Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J. Cardiovasc. Pharmacol. 46: 727-734